Search

Author/Creator Holeckova, Petra

1. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Issue 10212 (23rd November 2019)

Authors:
Burtness, Barbara; Harrington, Kevin J; Greil, Richard; Soulières, Denis; Tahara, Makoto; de Castro, Gilberto; Psyrri, Amanda; Basté, Neus; Neupane, Prakash; Bratland, Åse; Fuereder, Thorsten; Hughes, Brett G M; Mesía, Ricard; Ngamphaiboon, Nuttapong; Rordorf, Tamara; Wan Ishak, Wan Zamaniah; Hon...
Journal:
Lancet
Issue:
Volume 394:Issue 10212(2019)
Page Start:
1915
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Issue 9 (September 2022)

Authors:
Powles, Thomas; Tomczak, Piotr; Park, Se Hoon; Venugopal, Balaji; Ferguson, Thomas; Symeonides, Stefan N; Hajek, Jaroslav; Gurney, Howard; Chang, Yen-Hwa; Lee, Jae Lyun; Sarwar, Naveed; Thiery-Vuillemin, Antoine; Gross-Goupil, Marine; Mahave, Mauricio; Haas, Naomi B; Sawrycki, Piotr; Burgents, Jo...
Journal:
Lancet oncology
Issue:
Volume 23:Issue 9(2022)
Page Start:
1133
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search